Clearside Biomedica announced the completion of the final participant visit in the Company’s ODYSSEY Phase 2b clinical trial of CLS-AX or axitinib injectable suspension, in neovascular age-related macular degeneration or wet AMD . With this milestone complete, the study database is being cleaned and verified. Then the database will be locked and the unblinded data will be analyzed, with topline results expected to be reported during the week of October 7, 2024.”The completion of our ODYSSEY trial represents a major accomplishment for Clearside and I would like to recognize the Clearside team for the hard work and dedication in conducting the trial and achieving this important milestone,” said George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer…
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
- Clearside Biomedical initiated with a Buy at Chardan
- Clearside Biomedical reports Q2 EPS (10c), consensus (13c)
- Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, August 12, 2024